NCT07320560 Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping
| NCT ID | NCT07320560 |
| Status | Recruiting |
| Phase | — |
| Sponsor | German Heart Institute |
| Condition | Atrial Fibrillation (AF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2026-01-15 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot study investigates if non-invasive global mapping can guide catheter ablation of atrial fibrillation (AF) by defining personalized targets based on the temporal Stability of local Atrial High-Rate Activity (SAHRA). The study also assesses efficacy and safety of this approach and evaluates potential signals of harm. The main questions it aims to answer are: * Does ablation of targets defined by non-invasive global mapping improve rates of acute atrial fibrillation termination? * Does such a personalized ablation approach reduce arrhythmia recurrence rates? Researchers will compare the results of the personalized ablation approach with comparable patients that had undergone a conventional "empirical" ablation approach (pulmonary vein isolation). Participants will: * Undergo a personalized catheter ablation approach employing both a non-invasive global mapping system and a conventional intracardiac mapping system * Visit the clinic 3, 6 and 12 months after ablation for clinical follow-up * Schedule a telephone visit 9 and 24 months after ablation for clinical follow-up
Eligibility Criteria
Inclusion Criteria: Ablation-naïve patients with: 1. Persistent AF planned for catheter ablation plus 2. Left atrial enlargement (LA diameter ≥45 mm or LA volume index ≥35ml/m2 or LA area ≥20 cm2) Exclusion Criteria: * Previous cardiac ablation * Age \<18 years * Pregnancy or lactation * Previous stroke/TIA * Severe left ventricular dysfunction (LVEF \<35%) * Renal failure (GFR \<30 ml/min) * Dermal disease or hypersensitivity predisposing for skin irritation or exanthema
Contact & Investigator
Till F Althoff, M.D.
PRINCIPAL INVESTIGATOR
German Heart Center of the Charitè, Berlin, Department of Cardiology, Angiology and Intensive Care Medicine
Frequently Asked Questions
Who can join the NCT07320560 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07320560 currently recruiting?
Yes, NCT07320560 is actively recruiting participants. Contact the research team at till.althoff@dhzc-charite.de for enrollment information.
Where is the NCT07320560 trial being conducted?
This trial is being conducted at Berlin, Germany, Frankfurt am Main, Germany, Lisbon, Portugal, Barcelona, Spain and 1 additional location.
Who is sponsoring the NCT07320560 clinical trial?
NCT07320560 is sponsored by German Heart Institute. The principal investigator is Till F Althoff, M.D. at German Heart Center of the Charitè, Berlin, Department of Cardiology, Angiology and Intensive Care Medicine. The trial plans to enroll 45 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.